PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsEluxadoline
Viberzi, Truberzi(eluxadoline)
Truberzi, Viberzi (eluxadoline) is a small molecule pharmaceutical. Eluxadoline was first approved as Viberzi on 2015-05-27. It is used to treat irritable bowel syndrome in the USA. It has been approved in Europe to treat diarrhea and irritable bowel syndrome. It is known to target mu-type opioid receptor and delta-type opioid receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
digestive system diseasesD004066
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Viberzi
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Eluxadoline
Tradename
Company
Number
Date
Products
VIBERZIAbbVieN-206940 RX2015-05-27
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
viberziNew Drug Application2024-07-24
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
irritable bowel syndromeEFO_0000555D043183K58
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Eluxadoline, Viberzi, Abbvie
96755872033-03-14DP
101886322033-03-14DP
110071792033-03-14DP
110902912033-03-14DP
111607922033-03-14DP
112296272033-03-14DP
113115162033-03-14DP
114845272033-03-14U-3475
77413562029-05-27DS, DP
86918602028-07-07DPU-1709
91150912028-07-07DS, DPU-1738
93644892028-07-07U-1709
97891252028-07-07DPU-1709, U-2152
77861582025-03-14DP
83440112025-03-14U-1709
86097092025-03-14DP
87723252025-03-14U-1709
92050762025-03-14U-1709
97005422025-03-14DP
102134152025-03-14DPU-2152
ATC Codes
A: Alimentary tract and metabolism drugs
— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
— A07D: Antipropulsives
— A07DA: Antipropulsives
— A07DA06: Eluxadoline
HCPCS
No data
Clinical
Clinical Trials
9 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DiarrheaD003967HP_0002014R19.7—442—9
Irritable bowel syndromeD043183EFO_0000555K58—232—7
SyndromeD013577———232—7
Malabsorption syndromesD008286EFO_0009554K90———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetes mellitusD003920HP_0000819E08-E13—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Urge urinary incontinenceD053202EFO_0006865N39.41—1———1
Fecal incontinenceD005242—R15—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameEluxadoline
INNeluxadoline
Description
Eluxadoline is an amino acid amide obtained by the formal condensation of the carboxy group of 4-carbamoyl-2,6-dimethyl-L-phenylalanine with the secondary amino group of 2-methoxy-5-({[(1S)-1-(4-phenylimidazol-2-yl)ethyl]amino}methyl)benzoic acid. It has mixed opioid receptor activity and is used for treatment of irritable bowel syndrome with diarrhoea. It has a role as a mu-opioid receptor agonist, a delta-opioid receptor antagonist, a kappa-opioid receptor agonist and a gastrointestinal drug. It is a member of imidazoles, a methoxybenzoic acid, a member of benzamides, a L-phenylalanine derivative and an amino acid amide.
Classification
Small molecule
Drug classanalgesics (mixed opiate receptor agonists/antagonists)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COc1ccc(CN(C(=O)[C@@H](N)Cc2c(C)cc(C(N)=O)cc2C)[C@@H](C)c2ncc(-c3ccccc3)[nH]2)cc1C(=O)O
Identifiers
PDB—
CAS-ID864821-90-9
RxCUI—
ChEMBL IDCHEMBL2159122
ChEBI ID85980
PubChem CID11250029
DrugBankDB09272
UNII ID45TPJ4MBQ1 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
OPRM1
OPRM1
OPRD1
OPRD1
Organism
Homo sapiens
Gene name
OPRM1
Gene synonyms
MOR1
NCBI Gene ID
4988
Protein name
mu-type opioid receptor
Protein synonyms
hMOP, MOP, Mu opiate receptor, Mu opioid receptor, mu opioid receptor hMOR-1a
Uniprot ID
Q9UN57
Mouse ortholog
Oprm1 (18390)
mu-type opioid receptor (Q9R1M0)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Viberzi – Allergan
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Viberzi – Ironwood Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Viberzi – Warner Chilcott
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 391 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,251 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use